Private company

SPK Acquisition Corp.

SPK Acquisition Corp. is an American biological products company, incorporated in Delaware.1 It is headquartered in Shanghai, China.1

Last updated Oct 21, 2026.

Overview

-$421.2KNet income, fiscal 20212
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersShanghai, China1
  • Incorporated inDE3
  • Business addressRoom 368, 302 Buwei, 211 Fute North Road,, Shanghai, F4 2001313
  • Filer category, Emerging growth company3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Fiscal year2021
Operating expenses$422.8K2
Operating income-$422.8K2
Net income-$421.2K2

Compare SPK Acquisition Corp. with another company

Corporate structure

SPK Acquisition Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of SPK Acquisition Corp.

  • SPK Acquisition Corp. Shanghai, China

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SPK Acquisition Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$259.2K7 Dec 31, 2021
Marketable securities, current$50.9M2 Dec 31, 2021

Leadership

Who has led SPK Acquisition Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ye (sophie) Tao2021

Chief financial officer

  1. Philip Chun-Hun Kwan2021
2025
Board members and other officers (5)

Timeline

  1. Dec 29, 20228-K Ended a material agreement; Other events13
  2. Dec 27, 20228-K Ended a material agreement; Other events14
  3. Sep 13, 20228-K Entered a material agreement; New debt or obligation; Bylaws or fiscal year changed15
  4. Jun 17, 20228-K Earlier financial statements no longer reliable16
  5. Jun 7, 20228-K Earlier financial statements no longer reliable17
  6. May 25, 20228-K Earlier financial statements no longer reliable18
  7. Feb 28, 20228-K Regulation FD disclosure19
  8. Feb 17, 20228-K Entered a material agreement; Regulation FD disclosure20
  9. Jun 7, 2021New chief executive Ye (sophie) Tao becomes CEO8

Filings

47 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 8 major events, 2 insider forms, 12 large holders, 19 other. The latest 20:

  1. Feb 15, 2023SC 13G/A EDGAR
  2. Feb 14, 2023SC 13G/A EDGAR
  3. Feb 14, 2023SC 13G/A EDGAR
  4. Feb 13, 2023SC 13G/A EDGAR
  5. Jan 5, 20234 EDGAR
  6. Dec 29, 2022RW EDGAR
  7. Dec 29, 20228-K/A EDGAR
  8. Dec 27, 20228-K EDGAR
  9. Dec 15, 20223 EDGAR
  10. Nov 14, 202210-Q EDGAR
  11. Oct 21, 2022S-4/A FORM S-4 EDGAR
  12. Sep 16, 2022SC 13G/A SCHEDULE 13G/A EDGAR
  13. Sep 13, 20228-K EDGAR
  14. Aug 22, 2022DEF 14A EDGAR
  15. Aug 19, 2022CORRESP EDGAR
  16. Aug 19, 2022PRER14A EDGAR
  17. Aug 19, 2022UPLOAD EDGAR
  18. Aug 18, 2022UPLOAD EDGAR
  19. Aug 17, 2022CORRESP EDGAR
  20. Aug 17, 2022PRER14A EDGAR

The 47 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How SPK Acquisition Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSPK Acquisition Corp.1
  • CIK0001848097
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • Business addressRoom 368, 302 Buwei, 211 Fute North Road,, Shanghai, F4 2001311
  • Phone86 134391298791
  • Shares outstanding1,505,079 as of Nov 14, 20226
  • Public float$0 as of Jun 30, 20212
  • On EDGAR sinceMar 1, 20211
  • Filings76 in all: 8-K (8), SC 13G (8), UPLOAD (7), 10-Q (6), 3 (6), SC 13G/A (6), CORRESP (5), 8-K/A (3)1
    All 29 form types

    S-4/A (3), 4 (2), NT 10-Q (2), PRER14A (2), S-1/A (2), 10-K (1), 10-K/A (1), 25-NSE (1), 424B4 (1), 425 (1), 8-A12B (1), CERT (1), DEF 14A (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), PRE 14A (1), RW (1), S-1 (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Feb 24, 2022
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) Aug 22, 2022
    Latest 8-K (8-K) Dec 27, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28